中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

4 records (took 0.009 seconds)

    ANTIBODIES, AND BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND HER2 AND/OR APLP2, CONJUGATES, AND USES THEREOF
    2.
    发明申请
    ANTIBODIES, AND BISPECIFIC ANTIGEN-BINDING MOLECULES THAT BIND HER2 AND/OR APLP2, CONJUGATES, AND USES THEREOF 审中-公开

    公开(公告)号：WO2019212965A1

    公开(公告)日：2019-11-07

    申请号：PCT/US2019/029640

    申请日：2019-04-29

    Applicant: REGENERON PHARMACEUTICALS, INC.

    Inventor： PEREZ BAY, Andres ,  ANDREEV, Julian ,  POTOCKY, Terra ,  DUAN, Xunbao

    IPC: C07K16/28 ,  C07K16/32 ,  A61P35/00 ,  A61K47/68

    Abstract: The protein known as human epidermal growth factor 2 (HER2) is expressed in breast cancer cells and its expression is correlated with aggressive tumor growth. The present invention provides novel full-length human (IgG) antibodies that bind to human HER2 (monospecific antibodies) or to APLP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both HER2 and APLP2 and mediate internalization and degradation of HER2 via the APLP2 complex in the presence of HER2-expressing tumors. Described are bispecific antigen-binding molecules and ADCs comprising a first antigen-binding domain that specifically binds human APLP2, and a second antigen-binding domain that specifically binds human HER2. The described bispecific ADCs are capable of inhibiting the growth of certain tumors expressing HER2 and may be useful for the treatment of breast cancer and disorders in which targeting a therapeutic agent to HER2-expressing tumor cell is desirable and/or therapeutically beneficial. For example, the bispecific antibodies of the invention are useful for the treatment of breast cancers, including breast cancers having a IHC2+ classification. The present invention also includes anti-HER2 antibody drug conjugates which inhibit tumor growth in vivo .

    ANTI-CD48 ANTIBODIES AND USES THEREOF
    4.
    发明申请
    ANTI-CD48 ANTIBODIES AND USES THEREOF 审中-公开
    抗CD48抗体及其用途

    公开(公告)号：WO2012047567A1

    公开(公告)日：2012-04-12

    申请号：PCT/US2011/053193

    申请日：2011-09-26

    Applicant: REGENERON PHARMACEUTICALS, INC ,  CLASSON, Brendan, J. ,  KOSTIC, Ana ,  DUAN, Xunbao

    Inventor： CLASSON, Brendan, J. ,  KOSTIC, Ana ,  DUAN, Xunbao

    IPC: C07K16/28

    CPC classification number: C07K16/2803 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/33 ,  C07K2317/34 ,  C07K2317/35 ,  C07K2317/76 ,  C07K2317/92

    Abstract: The present invention provides antibodies that bind to CD48 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human CD48. In certain embodiments, the antibodies of the present invention block the binding of CD48 to one or more CD48 receptor. The antibodies of the invention are useful, inter alia, for the treatment of diseases and disorders associated with one or more CD48 biological activities, including the treatment of allergic conditions and other inflammatory conditions.

    Abstract translation: 本发明提供了结合CD48的抗体及其使用方法。 根据本发明的某些实施方案，抗体是与人CD48结合的完全人抗体。 在某些实施方案中，本发明的抗体阻断CD48与一种或多种CD48受体的结合。 本发明的抗体尤其用于治疗与一种或多种CD48生物活性相关的疾病和病症，包括治疗过敏性疾病和其它炎性病症。

Patent Agency Ranking